Interview: Why instrument manufacturers and users must work together to meet future challenges in biopharmaceutical analysis 

Why instrument manufacturers and users must work together to meet future challenges in biopharmaceutical analysis

With new achievements and changes in biopharma nearly every month– from personalized medicines to artificial intelligence and automation – it is becoming increasingly challenging for players in the industry to keep up. 

Jennifer Römer, Expert in mass spectrometric protein characterization at Rentschler Biopharma, and Jens Meixner, Product Manager for CE and HPLC systems at Agilent Technologies, spoke with the Analytical Scientist about the complexities faced by instrument manufacturers and users in a rapidly evolving biopharmaceutical world and how these can be met through collaboration.  

 

Read the full interview here (external link)

Rentschler Biopharma news Latika Bhonsle-Deeng

Corporate Spokesperson

Rentschler Biopharma SE

Dr. Latika Bhonsle-Deeng
Head of Communications

Get in touch